0

Tag: Suzanne Oparil

Keynotes Announced for 11th Annual CMHC!

Boston, July 22, 2016––The Cardiometabolic Health Congress has announced 5 Keynote presentations have been scheduled for the 11th Annual CMHC, taking place October 5-8, 2016, at the Sheraton in Boston, MA. The 3 ½-day event has become the largest US-based, multidisciplinary conference focused solely on the prevention, diagnosis, and management of cardiovascular and metabolic diseases.

The increased number of Keynotes for this year’s Annual Meeting will address the growing areas of cardiometabolic disease management and are as follows: Read more

Update and Clinical Implications of the SPRINT Trial

The SPRINT trial created both excitement and controversy in the medical community when it was realized aggressive blood pressure lowering to a target of 120 mmHg resulted in significant reductions in cardiovascular events and all-cause mortality. These reductions were seen in all of SPRINT’s subgroups including those older than age 75, persons with previous CAD, and those with chronic kidney disease. In her Keynote presentation, “Update and Clinical Implications of the SPRINT Trial,” Suzanne Oparil, MD, one of the principal investigators of the trial, will discuss the benefits seen in SPRINT as well as its caveats while touching on some of the ongoing substudies, including a cost-effectiveness analysis and a mind outcomes study examining the question of whether aggressive blood pressure lowering preserves cognitive function and brain structure.